<DOC>
	<DOCNO>NCT01140412</DOCNO>
	<brief_summary>This open-label , fixed-sequence , multiple dose crossover study 2 cohort 14 healthy male and/or female subject , estimate effect maraviroc pharmacokinetics amprenavir ritonavir fosamprenavir/ritonavir pharmacokinetics maraviroc .</brief_summary>
	<brief_title>Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Healthy male and/or female subject age 21 55 year , inclusive . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 . Total body weight &gt; 45 kg ( 99 lb ) . History regular alcohol consumption exceed 14 drinks/week female 21 drinks/week male ( 1 drink = 5 ounce ( 150 mL ) wine 12 ounce ( 360 mL ) beer 1.5 ounce ( 45 mL ) hard liquor ) within 6 month screen . Use tobacco nicotinecontaining product excess equivalent 5 cigarette per day . Treatment investigational drug within 30 day ( determined local requirement , whichever long ) 5 halflives precede first dose study medication . Known hypersensitivity history allergy sulfonamide .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>maraviroc</keyword>
	<keyword>fosamprenavir</keyword>
	<keyword>drug interaction</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>HIV</keyword>
	<keyword>AIDS</keyword>
	<keyword>CCR5</keyword>
	<keyword>protease inhibitor</keyword>
</DOC>